Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSK16149 in Chinese Patients With Postherpetic Neuralgia
NCT05140863Phase 3Completed
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Nov 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of crisugabalin besilate in postherpetic neuralgia (PHN) (3 arms), sponsored by Haisco Pharmaceutical Group Co., Ltd. Primary endpoint: Average Daily Pain Score at 12 weeks. Started Nov 2021; status: completed.
02
Drugs
crisugabalin besilate
03
Conditions
postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on NCT05140863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05140863.